VEGF (Vascular Endothelial Growth Factor) Inhibition and Hypertension: Does Microvascular Rarefaction Play a Role?

Ferdinand A. C. le Noble; Jean-Jacques Mourad; Bernard I. Levy; Harry A. J. Struijker-Boudier

doi:10.1161/HYPERTENSIONAHA.122.19427

VEGF (Vascular Endothelial Growth Factor) Inhibition and Hypertension: Does Microvascular Rarefaction Play a Role?

Ferdinand A. C. le Noble, Jean-Jacques Mourad, Bernard I. Levy, Harry A. J. Struijker-Boudier^*

^*Corresponding author for this work

Research output: Contribution to journal › (Systematic) Review article › peer-review

Abstract

Drugs acting by inhibition of the angiogenic action of VEGF (vascular endothelial growth factor) have become major instruments in the treatment of cancer. The downside of their favorable effects in cancer treatment is their frequent cardiovascular side effects. The most consistent finding thus far on the cardiovascular side effects of VEGF inhibitors is the high incidence of hypertension. In this short review, we discuss the evidence that hypertension occurring during VEGF inhibitor treatment is caused by microvascular rarefaction. After a review of the role of VEGF in microvascular growth and differentiation, we present evidence from studies in experimental models of hypertension as well as clinical studies on the microvascular network changes during and after VEGF inhibitor treatment.

Original language	English
Pages (from-to)	901-911
Number of pages	11
Journal	Hypertension
Volume	80
Issue number	5
DOIs	https://doi.org/10.1161/HYPERTENSIONAHA.122.19427
Publication status	Published - 1 May 2023

Keywords

angiogenesis
hypertension
microcirculation
rarefaction
tyrosine kinase inhibitors
ARTERIAL DIFFERENTIATION
CAPILLARY DENSITY
BLOOD-PRESSURE
CELL BEHAVIOR
ANGIOGENESIS
BEVACIZUMAB
DLL4
MECHANISMS
THERAPY
TARGET

Access to Document

10.1161/HYPERTENSIONAHA.122.19427

Cite this

@article{f35395c07d784321bf2abc8527831411,

title = "VEGF (Vascular Endothelial Growth Factor) Inhibition and Hypertension: Does Microvascular Rarefaction Play a Role?",

abstract = "Drugs acting by inhibition of the angiogenic action of VEGF (vascular endothelial growth factor) have become major instruments in the treatment of cancer. The downside of their favorable effects in cancer treatment is their frequent cardiovascular side effects. The most consistent finding thus far on the cardiovascular side effects of VEGF inhibitors is the high incidence of hypertension. In this short review, we discuss the evidence that hypertension occurring during VEGF inhibitor treatment is caused by microvascular rarefaction. After a review of the role of VEGF in microvascular growth and differentiation, we present evidence from studies in experimental models of hypertension as well as clinical studies on the microvascular network changes during and after VEGF inhibitor treatment.",

keywords = "angiogenesis, hypertension, microcirculation, rarefaction, tyrosine kinase inhibitors, ARTERIAL DIFFERENTIATION, CAPILLARY DENSITY, BLOOD-PRESSURE, CELL BEHAVIOR, ANGIOGENESIS, BEVACIZUMAB, DLL4, MECHANISMS, THERAPY, TARGET",

author = "{le Noble}, {Ferdinand A. C.} and Jean-Jacques Mourad and Levy, {Bernard I.} and Struijker-Boudier, {Harry A. J.}",

year = "2023",

month = may,

day = "1",

doi = "10.1161/HYPERTENSIONAHA.122.19427",

language = "English",

volume = "80",

pages = "901--911",

journal = "Hypertension",

issn = "0194-911X",

publisher = "LIPPINCOTT WILLIAMS & WILKINS",

number = "5",

}

TY - JOUR

T1 - VEGF (Vascular Endothelial Growth Factor) Inhibition and Hypertension

T2 - Does Microvascular Rarefaction Play a Role?

AU - le Noble, Ferdinand A. C.

AU - Mourad, Jean-Jacques

AU - Levy, Bernard I.

AU - Struijker-Boudier, Harry A. J.

PY - 2023/5/1

Y1 - 2023/5/1

N2 - Drugs acting by inhibition of the angiogenic action of VEGF (vascular endothelial growth factor) have become major instruments in the treatment of cancer. The downside of their favorable effects in cancer treatment is their frequent cardiovascular side effects. The most consistent finding thus far on the cardiovascular side effects of VEGF inhibitors is the high incidence of hypertension. In this short review, we discuss the evidence that hypertension occurring during VEGF inhibitor treatment is caused by microvascular rarefaction. After a review of the role of VEGF in microvascular growth and differentiation, we present evidence from studies in experimental models of hypertension as well as clinical studies on the microvascular network changes during and after VEGF inhibitor treatment.

AB - Drugs acting by inhibition of the angiogenic action of VEGF (vascular endothelial growth factor) have become major instruments in the treatment of cancer. The downside of their favorable effects in cancer treatment is their frequent cardiovascular side effects. The most consistent finding thus far on the cardiovascular side effects of VEGF inhibitors is the high incidence of hypertension. In this short review, we discuss the evidence that hypertension occurring during VEGF inhibitor treatment is caused by microvascular rarefaction. After a review of the role of VEGF in microvascular growth and differentiation, we present evidence from studies in experimental models of hypertension as well as clinical studies on the microvascular network changes during and after VEGF inhibitor treatment.

KW - angiogenesis

KW - hypertension

KW - microcirculation

KW - rarefaction

KW - tyrosine kinase inhibitors

KW - ARTERIAL DIFFERENTIATION

KW - CAPILLARY DENSITY

KW - BLOOD-PRESSURE

KW - CELL BEHAVIOR

KW - ANGIOGENESIS

KW - BEVACIZUMAB

KW - DLL4

KW - MECHANISMS

KW - THERAPY

KW - TARGET

U2 - 10.1161/HYPERTENSIONAHA.122.19427

DO - 10.1161/HYPERTENSIONAHA.122.19427

M3 - (Systematic) Review article

C2 - 36748474

SN - 0194-911X

VL - 80

SP - 901

EP - 911

JO - Hypertension

JF - Hypertension

IS - 5

ER -

VEGF (Vascular Endothelial Growth Factor) Inhibition and Hypertension: Does Microvascular Rarefaction Play a Role?

Abstract

Keywords

Access to Document

Fingerprint

Cite this